Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Samples Laura, Sadrzadeh Hossein, Frigault Matthew J, Jacobson Caron A, Hamadani Mehdi, Gurumurthi Ashwath, Strati Paolo, Shouval Roni, Noy Ariela, Riedell Peter A, Dahiya Saurabh, Maloney David G, Till Brian G, Hirayama Alexandre V, Gauthier Jordan, Gopal Ajay K, Smith Stephen D, Poh Christina, Lynch Ryan, Ujjani Chaitra, Di Mengyang, Raghunathan Vikram, Shakib-Azar Mehrdad, Naresh Kikkeri N, Gooley Ted A, Yared Jean, Jain Michael D, Locke Frederick L, Leslie Lori Ann, Epperla Narendranath, Ghosh Monalisa, Skarbnik Alan, Hill Brian T, Kamdar Manali K, Ortiz-Maldonado Valentin, Martinez-Cibrian Nuria, Shune Leyla, Shadman Mazyar
Аннотация
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.